TY - JOUR T1 - High-Plex and High-throughput Digital Spatial Profiling of non-small-cell lung cancer (NSCLC) JF - medRxiv DO - 10.1101/2020.07.22.20160325 SP - 2020.07.22.20160325 AU - James Monkman AU - Touraj Taheri AU - Majid Ebrahimi Warkiani AU - Connor O’leary AU - Rahul Ladwa AU - Derek Richard AU - Ken O’ Byrne AU - Arutha Kulasinghe Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/24/2020.07.22.20160325.abstract N2 - Profiling the tumour microenvironment(TME) has been informative in understanding the underlying tumour-immune interactions. Multiplex immunohistochemistry(mIHC) coupled with molecular barcoding technologies have revealed greater insights into the TME. In this study, we utilised the Nanostring GeoMX™ Digital Spatial Profiler (DSP) platform to profile a NSCLC tissue microarray for protein markers across immune cell profiling, immuno-oncology(IO) drug target, immune activation status, immune cell typing, and pan-tumour protein modules. Regions of interest(ROIs) were selected that described tumour, TME and normal adjacent tissue(NAT) compartments. Our data revealed that paired analysis (n=18) of patient matched compartments indicated that the TME was significantly enriched in CD27, CD3, CD4, CD44, CD45, CD45RO, CD68, CD163, and VISTA relative to tumour. Unmatched analysis indicated that the NAT(n=19) was significantly enriched in CD34, fibronectin, IDO1, LAG3, ARG1 and PTEN when compared to the TME(n=32). Univariate Cox proportional hazards indicated that the presence of cells expressing CD3(HR:0.5, p=0.018), CD34(HR:0.53, p=0.004) and ICOS (HR:0.6, p=0.047) in tumour compartments were significantly associated with improved overall survival(OS). We implemented both high-plex and high-throughput methodologies to the discovery of protein biomarkers and molecular phenotypes within biopsy samples and demonstrate the power of such tools for a new generation of pathology research.Conflict of interest statement The authors have declared that no conflict of interest exists.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Princess Alexandra Hospital Foundation grant for KOB. AK is supported by an NHMRC ECF Fellowship (APP1157741) and Cure Cancer (APP1182179).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Queensland University of Technology Human Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data from this study will be deposited in a publicly archived database. ER -